Melanoma (Skin) Clinical Trial
Official title:
Efficacy of Web-Based Instruction on Skin Cancer Triage
RATIONALE: Computer-based continuing education courses may be effective in improving the
skills of primary care doctors to identify skin cancer risk factors, perform skin cancer
exams, and counsel patients. They may also improve the skills of primary care doctors to
assess and counsel patients on their weight, diet, and physical activity.
PURPOSE: This randomized clinical trial is studying how well computer-based continuing
education courses work in improving doctors' ability to perform skin cancer or weight
control exams and counseling during routine office visits.
OBJECTIVES:
Primary
- Compare the efficacy of a continuing education course designed to improve primary care
physician performance in examination and counseling of patients about skin cancer vs a
continuing education course designed to improve physician assessment of weight
management.
- Evaluate physician performance of skin examination during routine patient visits at 12
months after completion of the skin cancer continuing education course.
- Evaluate physician counseling around skin cancer issues.
Secondary
- Evaluate the efficacy of the skin cancer continuing education course in improving
physician skin cancer triage skills and in changing physician attitudes and knowledge
regarding skin cancer issues.
- Assess improvements in physician assessment of weight, diet, and physical activity.
OUTLINE: This is a randomized, multicenter study. Physicians are stratified according to
participating center. Physicians are randomized to 1 of 2 intervention arms.
- Arm I (skin cancer continuing education course): Physicians complete a 1-hour
continuing education course on skin cancer. The course is available to the physician as
a reference for up to 12 months. Physicians complete an online test at baseline,
immediately after the course is completed, and at 1 month and 12 months after course
completion to assess their knowledge, attitudes, skill, and practices towards skin
examination and skin cancer counseling.
Patients are interviewed by telephone within 1 week after a routine office visit with their
physician to assess the physician's skin assessment and skin cancer counseling practices.
The interviews are conducted prior to and at 1 month and 12 months after the physician
completes the continuing education course.
- Arm II (weight control continuing education course): Physicians complete a 1-hour
continuing education course on weight, dietary, and physical activity assessment and
counseling. The course is available to the physician as a reference for up to 12
months. Physicians complete an online test at baseline, immediately after the course is
completed, and at 1 month and 12 months after course completion to assess their
knowledge, attitudes, skill, and practices towards weight, dietary, and physical
activity assessment and counseling.
Patients are interviewed by telephone within 1 week after a routine office visit with their
physician to assess the physician's weight, dietary, and physical activity assessment and
counseling practices. The interviews are conducted prior to and at 1 month and 12 months
after the physician completes the continuing education course.
PROJECTED ACCRUAL: A total of 50 physicians and 4,500 patients will be accrued for this
study.
;
Allocation: Randomized
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |